AU Patent

AU2017215825A1 — Method for treating cancer patients with severe renal impairment

Assigned to Les Laboratoires Servier SAS · Expires 2018-08-23 · 8y expired

What this patent protects

A cancer treatment method for cancer patients with severe renal dysfunction is provided. This cancer treatment method, for patients having a creatinine clearance of greater than or equal to 15 mL/min and less than 30 mL/min, involves orally dosing the patient with a 30-50 mg/m

USPTO Abstract

A cancer treatment method for cancer patients with severe renal dysfunction is provided. This cancer treatment method, for patients having a creatinine clearance of greater than or equal to 15 mL/min and less than 30 mL/min, involves orally dosing the patient with a 30-50 mg/m

Drugs covered by this patent

Patent Metadata

Patent number: AU2017215825A1
Jurisdiction: AU
Classification: —
Expires: 2018-08-23
Drug substance claim: No
Drug product claim: No
Assignee: Les Laboratoires Servier SAS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.